Evidence for a ‘window of opportunity’ in hidradenitis suppurativa treated with adalimumab: a retrospective, real‐life multicentre cohort study*Angelo Valerio Marzano, Ketty Peris, Giovanni Genovese et al.|British Journal of Dermatology|2020Cited by 175
Hidradenitis Suppurativa in a Large Cohort of Italian Patients: Evaluation of the Burden of DiseaseGabriella Fabbrocini, Giuseppe Argenziano, Giulia Ruina et al.|Dermatology|2021Cited by 18
Effectiveness of guselkumab in patients with facial and/or genital psoriasis: Interim analysis results at Week 12 from the GULLIVER studyClaudio Bonifati, Giuseppe Argenziano, Serena Lembo et al.|Journal of the European Academy of Dermatology and Venereology|2024Cited by 10
Long-Term Persistence Rate of Secukinumab in Psoriatic Patients: A Six-Year Multicenter, Real-World Experience, Retrospective StudyMarco Galluzzo, Pietro Rubegni, Filomena Russo et al.|Journal of Clinical Medicine|2024Cited by 7
Guidelines How to Integrate Surgery and Targeted Therapy with Biologics for the Treatment of Hidradenitis Suppurativa: Delphi Consensus Statements from an Italian Expert PanelAnnamaria Offidani, Francesca Prignano, Angelo Valerio Marzano et al.|Dermatology|2024Cited by 5